GNH USA

Europe — EMA

Navelbine (Vinorelbine)

GNH USA supplies Navelbine (Vinorelbine), a Vinca alkaloid for non‑small cell lung cancer and metastatic breast cancer. Request a quote for global supply.

Vinorelbine

Request sourcing

1
Pack/s

What is Vinorelbine?

Vinorelbine, the active ingredient in Navelbine, is a Vinca alkaloid presented as an oral capsule for oral use. It treats certain types of cancer, specifically non‑small cell lung cancer and metastatic breast cancer, in adult patients.

GNH USA supplies Navelbine as a licensed, GDP‑compliant international pharmaceutical supplier serving oncology centres, hospitals and pharmacies worldwide.

What is Vinorelbine used for?

Vinorelbine is used in the treatment of solid tumours that are responsive to antimitotic therapy.

Non‑small cell lung cancer: improves disease control and survival in adult patients. Metastatic breast cancer: slows tumour progression in patients who have received prior chemotherapy.

What are the side effects of Vinorelbine?

Vinorelbine may cause a range of adverse reactions that vary in frequency and severity.

Common Side Effects: - Nausea: upset stomach often occurring after dosing. - Neutropenia: reduced white blood cell count increasing infection risk. - Fatigue: persistent tiredness not relieved by rest. - Constipation: difficulty passing stools.

Serious or Rare Side Effects: - Severe neutropenia with fever: may require hospitalization. - Pulmonary toxicity: interstitial pneumonitis or fibrosis. - Allergic reactions: rash, swelling, or anaphylaxis. - Peripheral neuropathy: tingling or numbness in extremities. - Cardiac arrhythmia: irregular heart rhythm observed in rare cases.

What precautions apply to Vinorelbine?

Before initiating therapy, clinicians should assess patient-specific risk factors and monitor for toxicity.

Monitor blood counts: perform regular CBC to detect neutropenia. Assess liver function: adjust dose in hepatic impairment. Evaluate pulmonary status: avoid in patients with pre‑existing severe lung disease. Avoid use in pregnancy: contraindicated due to fetal risk. Store at room temperature: keep in original pack, protect from moisture and light.

What does Vinorelbine interact with?

Vinorelbine may interact with other medicines, altering its safety or effectiveness.

Major Interactions (Avoid): - Strong CYP3A4 inhibitors (e.g., ketoconazole): increase vinorelbine exposure and toxicity. - Concurrent myelosuppressive agents: exacerbate bone‑marrow suppression. - CYP3A4 inducers (e.g., rifampicin): reduce vinorelbine efficacy.

Moderate Interactions (Monitor Closely): - Antiemetics that affect QT interval (e.g., ondansetron): monitor cardiac rhythm. - Anticoagulants: increased risk of bleeding. - Other vinca alkaloids: additive neurotoxicity; avoid co‑administration.

Frequently asked questions

What is Navelbine used for?+
Navelbine is the brand name for vinorelbine, an antineoplastic agent indicated for the treatment of adult patients with non‑small cell lung cancer and metastatic breast cancer, typically after prior chemotherapy. It works by interfering with cell division, helping to control tumor growth.
How does vinorelbine work?+
Vinorelbine belongs to the Vinca alkaloid class and exerts its anticancer effect by binding to tubulin, inhibiting microtubule polymerisation. This prevents formation of the mitotic spindle, arrests cells in the M‑phase of the cell cycle and ultimately leads to apoptosis of rapidly dividing tumour cells.
What is the usual dose of Navelbine?+
The specific dose of Navelbine is determined by the prescribing physician based on the patient’s clinical condition, body surface area, prior therapies and laboratory parameters. Dosing regimens may vary, and the medication should be administered exactly as directed in the individual prescription.
Is Navelbine safe during pregnancy or breastfeeding?+
Vinorelbine is classified as pregnancy category D, indicating evidence of fetal risk; it should be avoided in pregnant women unless the potential benefit justifies the risk. Breastfeeding is not recommended because the drug can be excreted in milk and may harm the infant.
How do I order Navelbine from GNH USA?+
To place an order, submit an enquiry on the product page at gnh-usa.com specifying the required quantity of Navelbine. GNH USA works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.
How does Navelbine compare with other antineoplastic agents?+
Compared with other Vinca alkaloids such as vincristine or vinblastine, vinorelbine has a distinct toxicity profile, with relatively lower neurotoxicity but higher rates of neutropenia and pulmonary effects. Its oral capsule formulation offers convenience over intravenous alternatives, though efficacy and safety must be evaluated against the specific tumour type and patient characteristics.
What are the storage and handling requirements for Navelbine?+
Navelbine oral capsules should be stored at room temperature, below 25 °C, in the original packaging to protect them from moisture and light. Keep the product out of reach of children and do not use if the packaging is damaged or the capsules appear discoloured.
How is Navelbine administered?+
Navelbine is supplied as oral capsules that are taken with water, usually on an empty stomach or as directed by the treating oncologist. The capsules should be swallowed whole and not crushed or chewed, and the dosing schedule is set by the prescriber, often on a weekly or bi‑weekly basis.
What are the most serious risks to watch for with Navelbine?+
The most serious adverse reactions to vinorelbine include severe neutropenia that can lead to infection, pulmonary toxicity such as interstitial pneumonitis, and rare but life‑threatening allergic reactions. Patients should be monitored closely for signs of fever, respiratory distress or hypersensitivity, and treatment should be adjusted or discontinued as needed.
Who should not use Navelbine?+
Navelbine is contraindicated in patients with known hypersensitivity to vinorelbine or other Vinca alkaloids, in pregnant women unless absolutely necessary, and in individuals with severe hepatic impairment without dose adjustment. Caution is also advised for patients with pre‑existing lung disease, uncontrolled infections, or those receiving concurrent myelosuppressive therapy.
Information provided on this page is for educational use by procurement and clinical professionals. Always consult a licensed healthcare provider for medical advice and prescribing decisions. GNH USA supplies this product subject to applicable regulatory and licensing requirements.
Send a sourcing enquiry for this product →

Product details

Drug
Vinorelbine
Route
Oral Use
Manufacturer
Pierre Fabre Medicament
Origin
EU

Related products

Vinorelbine 10 mg/mL

Vinorelbine 10 mg/mL

Vinorelbine · 10 mg/mL

Vinorelbine
INJECTION, SOLUTION
Sagent Pharmaceuticals
USA
Vinorelbine 10 mg/mL

Vinorelbine 10 mg/mL

Vinorelbine · 10 mg/mL

Vinorelbine
INJECTION, SOLUTION
Sagent Pharmaceuticals
USA
Navelbine

Navelbine

Vinorelbine

Pierre Fabre Medicament
EU
Navelbine

Navelbine

Vinorelbine

Pierre Fabre Medicament
EU